Literature DB >> 34181486

A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma.

Leo Mascarenhas1,2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34181486      PMCID： PMC8425823          DOI： 10.1200/JCO.21.01296

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  49 in total

1.  Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Authors:  Pooja Hingorani; Edoardo Missiaglia; Janet Shipley; James R Anderson; Timothy J Triche; Mauro Delorenzi; Julie Gastier-Foster; Michele Wing; Douglas S Hawkins; Stephen X Skapek
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531

Review 2.  Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned.

Authors:  Carola A S Arndt; Gianni Bisogno; Ewa Koscielniak
Journal:  Cancer Treat Rev       Date:  2018-06-19       Impact factor: 12.111

3.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

Authors:  David S Hong; Steven G DuBois; Shivaani Kummar; Anna F Farago; Catherine M Albert; Kristoffer S Rohrberg; Cornelis M van Tilburg; Ramamoorthy Nagasubramanian; Jordan D Berlin; Noah Federman; Leo Mascarenhas; Birgit Geoerger; Afshin Dowlati; Alberto S Pappo; Stefan Bielack; François Doz; Ray McDermott; Jyoti D Patel; Russell J Schilder; Makoto Tahara; Stefan M Pfister; Olaf Witt; Marc Ladanyi; Erin R Rudzinski; Shivani Nanda; Barrett H Childs; Theodore W Laetsch; David M Hyman; Alexander Drilon
Journal:  Lancet Oncol       Date:  2020-02-24       Impact factor: 41.316

4.  Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:  Leo Mascarenhas; Yueh-Yun Chi; Pooja Hingorani; James R Anderson; Elizabeth R Lyden; David A Rodeberg; Daniel J Indelicato; Simon C Kao; Roshni Dasgupta; Sheri L Spunt; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2019-09-12       Impact factor: 44.544

5.  Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes.

Authors:  Lin Xu; Yanbin Zheng; Jing Liu; Dinesh Rakheja; Sydney Singleterry; Theodore W Laetsch; Jack F Shern; Javed Khan; Timothy J Triche; Douglas S Hawkins; James F Amatruda; Stephen X Skapek
Journal:  Cell Rep       Date:  2018-07-03       Impact factor: 9.423

6.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

9.  Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.

Authors:  Emily Hibbitts; Yueh-Yun Chi; Douglas S Hawkins; Frederic G Barr; Julie A Bradley; Roshni Dasgupta; William H Meyer; David A Rodeberg; Erin R Rudzinski; Sheri L Spunt; Stephen X Skapek; Suzanne L Wolden; Carola A S Arndt
Journal:  Cancer Med       Date:  2019-08-27       Impact factor: 4.452

10.  Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Christine M Heske; Yueh-Yun Chi; Rajkumar Venkatramani; Minjie Li; Michael A Arnold; Roshni Dasgupta; Susan M Hiniker; Douglas S Hawkins; Leo Mascarenhas
Journal:  Cancer       Date:  2020-11-20       Impact factor: 6.921
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.